Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

15.63 +0.13 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alpine Immune Sciences Inc

< Previous 1 2 3 Next >
The Latest Analyst Ratings for Alpine Immune Sciences
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
What 8 Analyst Ratings Have To Say About Alpine Immune Sciences
Via Benzinga
Analyst Expectations for Alpine Immune Sciences's Future
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index uses proprietary data to look at stocks with increased interest from investors. 
Via Benzinga
Apple, Coinbase Global, Fortinet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Alpine Immune Sciences Stock Trading Higher Today?
Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
Recap: Alpine Immune Sciences Q1 Earnings
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
Earnings Preview: Alpine Immune Sciences
Via Benzinga
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
Via Benzinga
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
Alpine Immune Sciences Inc (NASDAQ: ALPN)  
Via Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role
RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate -... 
Via Benzinga
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
US Stock Futures Edge Higher; All Eyes On Fed Decision
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq... 
Via Benzinga
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Alpine Immune Sciences's Return On Capital Employed Overview
Benzinga Pro data, Alpine Immune Sciences (NASDAQ:ALPN) reported Q2 sales of $5.29 million. Earnings fell to a loss of $18.10 million, resulting in a 140.44% decrease from last quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
Alpine Immune Sciences: Q2 Earnings Insights
  Alpine Immune Sciences (NASDAQ:ALPN) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate
Via Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.